Login / Signup

Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study.

Jitao WangQiran ZhangJingwen AiDengxiang LiuChuan LiuHuiling XiangYe GuYing GuoJiaojian LvYifei HuangYanna LiuDan XuShubo ChenJinlong LiQianqian LiJing LiangLi BianZhen ZhangXiaoqing GuoYinong FengLuxiang LiuXuying ZhangYanliang ZhangFaren XieShujun JiangWei QinXiaodong WangWei RaoQun ZhangQiuju TianYing ZhuQingwei CongJuan XuZhiyun HouNina ZhangAiguo ZhangHongmei ZuYun WangZhaolan YanXiufang DuAifang HouYan YanYuanwang QiuHangyuan WuShengjuan HuYanhong DengJiansong JiJie YangJiansheng HuangZhongwei ZhaoShengqiang ZouHailei JiGuohong GeLi ZhongSong HeXiaosong YanBian Ba YangzhenCi QuLiting ZhangShiying YangXiaoqin GaoMuhan LvQingliang ZhuXinxin XuQing-Lei ZengXiaolong QiWenhong Zhang
Published in: Hepatology international (2022)
Inactivated COVID-19 vaccinations are safe with acceptable immunogenicity in cirrhotic patients, and Child-Pugh score of B and C levels is associated with hyporesponsive to COVID-19 vaccination.
Keyphrases
  • sars cov
  • coronavirus disease
  • end stage renal disease
  • respiratory syndrome coronavirus
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • prognostic factors